类风湿关节炎相关间质性肺病或支气管扩张住院风险:匹配队列研究
基于Mass General Brigham Biobank的回顾性匹配队列研究,比较221例RA-LD(151例RA-ILD和70例RA-BR)与980例无肺病RA对照。RA-LD总体住院风险调整IRR 1.73(95%CI 1.57-1.91),呼吸相关住院风险调整IRR 5.13(95%CI 3.80-6.94);RA-ILD的ICU入住风险调整IRR 1.99(95%CI 1.81-2.18)。MUC5B启动子变异和糖皮质激素使用与更高呼吸住院风险相关。
要点
- RA-LD患者总体住院和呼吸住院风险显著高于无肺病RA患者。
- RA-ILD患者ICU入住风险也显著增加。
- MUC5B启动子变异和糖皮质激素使用与呼吸住院风险升高相关。
核心结论
- RA-ILD和RA-BR均与较无肺病RA对照显著更高的总体住院和呼吸住院风险相关。
- MUC5B启动子变异和糖皮质激素使用可能使患者处于更高急性医疗使用风险。
研究设计与样本
- 回顾性匹配队列研究,使用Mass General Brigham Biobank数据。
- 比较221例经病历和胸部影像证实的RA-LD(151例RA-ILD和70例RA-BR)与980例无肺病RA对照。
- 部分患者进行了MUC5B启动子变异基因分型。
- 采用倾向评分调整协变量的多变量泊松回归模型估计发生率比(IRR)及95%CI。
主要发现
- RA-LD总体住院调整IRR 1.73(95%CI 1.57-1.91),呼吸住院调整IRR 5.13(95%CI 3.80-6.94)。
- RA-ILD ICU入住调整IRR 1.99(95%CI 1.81-2.18)。
- MUC5B启动子变异和糖皮质激素使用分别与更高呼吸住院风险相关。
- 更频繁的临床访视和女性性别与更低风险相关。
临床怎么用
- 对RA-LD患者应早期进行风险分层和主动监测,以指导个体化管理。
- 关注MUC5B启动子变异和糖皮质激素使用等风险因素,可能有助于识别高急性医疗使用风险患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate hospitalization risk and identify factors associated with respiratory hospitalization in rheumatoid arthritis-associated lung disease (RA-LD). METHODS: We conducted a retrospective cohort study using the Mass General Brigham Biobank (Boston, Massachusetts), comparing RA-LD cases to matched RA comparators without lung disease (RA-no LD). RA-LD was verified by medical record review and chest imaging for clinically-apparent RA-associated interstitial lung disease (RA-ILD) and/or RA-associated bronchiectasis (RA-BR). A subset had genotyping performed for the MUC5B promoter variant. The co-primary outcomes were overall and respiratory hospitalizations. Incidence rate ratios (IRRs) with 95% confidence intervals (CI) were estimated using multivariable Poisson regression models, comparing RA-LD, RA-ILD, and RA-BR cases vs. RA-no LD comparators, adjusting for covariates by a propensity score. RESULTS: We analyzed 221 RA-LD cases (151 RA-ILD and 70 RA-BR) and 980 RA-no LD comparators. RA-LD, including RA-ILD and RA-BR, had higher risks of overall hospitalization (adjusted IRR 1.73, 95%CI 1.57-1.91) and respiratory hospitalization (adjusted IRR 5.13, 95%CI 3.80-6.94). RA-ILD also had increased risk of intensive care unit (ICU) admissions (adjusted IRR 1.99, 95%CI 1.81-2.18). The MUC5B promoter variant and glucocorticoid use were each associated with higher respiratory hospitalization risk, whereas more frequent clinic visits and female sex were associated with lower risk. CONCLUSION: RA-ILD and RA-BR were each associated with markedly higher risks of overall and respiratory hospitalization than RA-no LD comparators. Factors including the MUC5B promoter variant and glucocorticoid use may place patients at higher risk for acute care utilization. These findings support early risk stratification and proactive monitoring to guide personalized RA-LD management.
引用
- Zhang Q, Qi Y, Wang X, et al. Hospitalization risk in patients with rheumatoid arthritis-associated interstitial lung disease or bronchiectasis: A matched cohort study. Semin Arthritis Rheum. 2026. PMID: 42127546. doi:10.1016/j.semarthrit.2026.152996
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。